Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Ayurveda is one of the most advanced sciences of its times
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
Subscribe To Our Newsletter & Stay Updated